高级检索
当前位置: 首页 > 详情页

Tumor Innervation: From Bystander to Emerging Therapeutic Target for Cancer

文献详情

资源类型:
Pubmed体系:
机构: [1]Department of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, The Chinese University of Hong Kong, Hong Kong. [2]Department of Surgery, The Chinese University of Hong Kong, Hong Kong. [3]Department of Head and Neck Oncology, West China Hospital of Stomatology, Sichuan University, Chengdu 610065, China. [4]College of Pharmacy, Jinan University, Guangzhou 510632, China. [5]Department of Nephrology and Monash University Department of Medicine, Monash Medical Centre, Clayton, VIC 3168, Australia. [6]Key Laboratory for Regenerative Medicine of the Ministry of Education of China, School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong. [7]Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Shatin, Hong Kong. [8]Peter Hung Pain Research Institute, The Chinese University of Hong Kong, Hong Kong.
出处:

关键词: tumor innervation tumor–nerve crosstalk denervation therapy

摘要:
Innervation is ubiquitous in diseased tissues, including cancer. Increasing evidence suggests that innervation not only plays a direct role in cancer pain, but is also closely related to disease progression, including cancer growth, metastasis, and drug resistance. At the molecular level, tumor-associated nerves can interact with cancer cells and the tumor microenvironment through neurotrophic factors, thereby promoting tumor occurrence and development, and represent a potential intervention for solid tumors with nerve enrichment. By dissecting the transcriptome dynamics of cancer-associated neurons with single cell resolution, numbers of novel therapeutic targets for tumor denervation have been uncovered, including a novel phenomenon-Macrophage to Neuron-like cell Transition (MNT). This review systematically summarizes the latest research findings of tumor denervation, from molecular mechanisms to the innovative denervation strategies, paving the way for novel, safe, and effective cancer treatments in the clinic.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2025]版:
大类 | 3 区 生物学
小类 | 3 区 生化与分子生物学 3 区 化学:综合
最新[2025]版:
大类 | 3 区 生物学
小类 | 3 区 生化与分子生物学 3 区 化学:综合
第一作者:
第一作者机构: [1]Department of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, The Chinese University of Hong Kong, Hong Kong.
共同第一作者:
通讯作者:
通讯机构: [1]Department of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, The Chinese University of Hong Kong, Hong Kong. [7]Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Shatin, Hong Kong. [8]Peter Hung Pain Research Institute, The Chinese University of Hong Kong, Hong Kong.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:65780 今日访问量:0 总访问量:5151 更新日期:2025-12-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号